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Human adipose tissue is a major site of expression of inhibin beta B (INHBB) which homodimerizes to
form the novel adipokine activin B. Our aim was to determine if molecules needed for a local action of
activin B are expressed in adipose tissue.
Microarray analysis showed that adipose tissue expressed activin type I and II receptors and that the
expression of activin receptor-like kinase 7 (ALK7) was adipose tissue speciﬁc. In obesity discordant sib-
lings from the SOS Sib Pair study, adipose tissue ALK7 expression was higher in lean (n = 90) compared to
obese (n = 90) subjects (p = 4  1031). Adipose tissue ALK7 expression correlated with several measures
of body fat, carbohydrate metabolism and lipids. In addition, ALK7 and INHBB expression correlated but
only in lean subjects and in subjects with normal glucose tolerance.
We conclude that activin B may have local effects in adipose tissue and thereby inﬂuence obesity and
its comorbidities.
 2009 Elsevier Inc. Open access under CC BY license.Introduction
Activins were ﬁrst described as gonadal hormones and their
effects on reproduction have been extensively studied. Recent
studies show that activins are also produced by extragonadal tis-
sues where they have diverse effects [1]. Activins are formed by
homo or heterodimerization of related beta subunits, resulting in
several different activins [1]. In a search for adipocyte-speciﬁc
genes we found that the inhibin beta B gene (INHBB) is highly
expressed in human adipocytes and the corresponding protein
is present in the adipocyte cytoplasm [2]. Intracellular homodi-
merization of two INHBB subunits results in formation of activin
B, and the high expression of the INHBB gene in adipocytes
therefore suggest that adipose tissue is a major site of activin
B production.
Adipose tissue secretes a large variety of bioactive molecules,
often referred to as adipokines. The adipokines have local effects
or signal to other tissues, and they may play a central role in
obesity-related morbidities such as diabetes, cardiovascular dis-
ease, cancer and dyslipidemia [3]. Genes that are speciﬁcally ex-
pressed in a tissue are likely to inﬂuence important functions,holm).
Y license.and genes that are highly expressed in adipocytes may, there-
fore, affect adipose tissue function or obesity related disorders.
The unexpectedly high expression of INHBB in human adipo-
cytes, therefore, raises the question of how and where the novel
adipokine activin B exerts its action.
Activins belong to the TGF-b family of growth factors [1], and
most members of this family act in a paracrine or autocrine fash-
ion. The high expression of the INHBB subunit in adipose tissue
may contribute to circulating levels of activin B. However, activins
in the blood are bound to carrier proteins. Follistatin forms biolog-
ically inactive complexes with activin A and also reduces the activ-
ity of activin B [4,5]. Thus, it is likely that adipose tissue derived
activin B exerts its effects locally and this requires the expression
of signaling molecules.
Activins interact with receptor complexes consisting of two
receptors, type I and II, both of which are serine/threonine kinases
[6]. There are seven type I receptors, referred to as activin receptor-
like kinases (ALK) 1 to 7, and ALK4 and ALK7 appear to function as
type 1 receptors for activin B [1,6]. Activin receptor type II (ActR-II)
and ActR-IIB are the main type II receptors for activins [1,6]. We
have previously reported that some of the activin receptors are
expressed in human adipose tissue [2] but more detailed analysis
is lacking. The aim of this study was therefore to determine if
human adipose tissue expresses receptors needed for paracrine
or autocrine action of activin B.
310 L.M.S. Carlsson et al. / Biochemical and Biophysical Research Communications 382 (2009) 309–314Methods
Subjects. The SOS Sib Pair study includes 154 nuclear families
with BMI discordant sibling pairs (BMI difference P10 kg/m2)
resulting in a study population of 732 subjects. In this study, the
most extreme siblings according to BMI were chosen in each fam-
ily. Gender discordant sib pairs were excluded, resulting in 78 pairs
of sisters and 12 pairs of brothers.
For tissue distribution, adipose tissue biopsies from six healthy
volunteers (BMI range 22.4–29.3) were obtained. Adipocytes were
isolated as previously described [7,8]. Subjects received written
and oral information before giving written informed consent. The
Regional Ethics Committee in Gothenburg approved the studies.
Samplingsandexaminationswereperformedafter anovernight fast.
Tissue distribution of gene expression. DNA microarray expression
proﬁles (Human Genome U133 plus 2.0, Affymetrix, Santa Clara, CA)
from65human tissueswereacquired fromtheGEOdatabase (Dataset
GSE3526; http://www.ncbi.nlm.nih.gov/geo/). Each tissue was repre-
sentedbyproﬁles from3to9 subjects and thesewereused to calculate
an average expression proﬁle. For inhibin genes and activin receptor
genes, the average expression in the 65 tissues was calculated and
used for comparison with the adipose tissue expression. Probe sets
were identiﬁed using Nettaffx (http://www.affymetrix.com/analysis/
index.affx) and for each gene, the probe set with the highest signal
was used. The following probe sets were used; INHA (210141_s_at),
INHBA (210511_s_at), INHBB (205258_at), INHBC (207687_at), INHBE
(210587_at), ALK7 (1552519_at), ALK4 (205209_at), ActRII
(205327_s_at) and ActRIIB (236126_at).
For veriﬁcation of tissue distribution, RNA from adipose tissue
and adipocytes (prepared with RNeasy Lipid Tissue Mini Kit; Qia-
gen, Chatsworth, CA) and from the Human Total RNA Master Panel
II (Clontech Laboratories, Inc., Palo Alto, CA), was reversed tran-
scribed using the High Capacity cDNA RT kit (Applied Biosystems,
Foster City, CA). Reagents for real-time PCR analysis of ALK7
(Hs00377065_m1) and peptidyl-prolyl isomerase A (PPIA; endoge-
nous control, 4326316E) were from Applied Biosystems. cDNA cor-
responding to 10 ng RNA per reaction was used for real-time PCR in
the ABI PRISM 7900HT Sequence Detection System (Applied Bio-
systems). Serial dilution of cDNA synthesized from pooled RNA
was used to generate standard curves. PPIA expression was used
to normalize ALK7 expression between samples. All samples were
analyzed in triplicate.
Microarray analysis in the SOS Sib Pair study. Adipose tissue was
obtained by needle aspirations in the paraumbilical area. Total
RNA, cDNA and hybridization (Human Genome U133 plus 2.0,
Affymetrix) was performed as previously described [7–9]. Data
were analyzed using RMA. ALK7 expression was analyzed using
probe set 1552519_at and INHBB was analyzed using 205258_at.
Measurements in the SOS Sib Pair study.Measurements of anthro-
pometry, fat mass (FM), fat-free mass (FFM), blood pressure (BP),
fasting glucose, total cholesterol, triglycerides, high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), serum insulin, serum C peptide, and highly sensitive C-
reactive protein (hs-CRP) were performed at the Sahlgrenska Uni-
versity Hospital. Dual-energy X-ray absorptiometry (DEXA) was
performed with LUNAR DPX-L (Scanexport Medical, Helsingborg,
Sweden). The DEXA generates a three-compartment model consist-
ing of FM, lean tissue mass (LTM), and bone mineral content (BMC).
The FFM was calculated as LTM + BMC.
Statistics. Statistical analyseswere performedusing SPSS (version
16.0; SPSS, Chicago, IL, USA) and SAS (version 9.1). Values are given
as means ± SD unless stated otherwise. Correlation between ALK7,
INHBB expression and anthropometric and biochemical markers
were performed using the Spearman rank correlation test. Partial
correlationwasused to control for sex, age and fatmasswhenappro-priate. In order to obtain approximate normal distributions of
expression data, microarray signals in the whole SOS Sib Pair study
offspring cohort (n = 359) were transformed using Box–Cox power
transformations. Subsequently, expression data were standardized
to mean = 0 and variance = 1. Differences in gene expression
between lean and obese siblingswere assessed using a paired t-test.
A P value less than 0.05 (two-sided)was considered statistically sig-
niﬁcant. Linear relationships between ALK7 and INHBB transcript
levels that differed between subgroups (lean vs. obese, or insulin
resistant vs. insulin sensitive) were assessed in generalized linear
models in which subgroup class was included as a covariate beside
the transcript level. A p-value <0.05 for the interaction between sub-
group class and transcript level was taken as evidence of a signiﬁ-
cantly different linear relationship between subgroup classes.Results
Adipose tissue expression of activin subunits and activin receptors
Adipose tissue expression levels of inhibin genes and activin
receptorgenesweremeasured andcomparedwith themeanexpres-
sion levels of these genes in 65 different human tissues, hereafter
referred to as reference tissues. In line with our previous results
[2], expression of the INHBB gene was high in adipose tissue com-
pared to the reference tissues (Fig. 1A), while the genes encoding
the other activin subunits displayed adipose tissue expression levels
equal to or lower than the mean expression in the reference tissues.
Among the type I activin receptor genes, ALK4 and ALK7 are
known to mediate activin B action [6,10]. The adipose tissue
expression of the ALK4 gene was lower than the mean expression
in the reference tissues. In contrast, the ALK7 gene displayed the
highest expression in human adipose tissue with more than 4-fold
higher expression than in the reference tissues. ALK7 expression
was also detected in mammary gland and in some regions of the
brain, including putamen, nucleus accumbens and hippocampus
(data not shown). The high expression of the ALK7 gene in human
adipose tissue was veriﬁed by real-time PCR using a panel of 18
human tissues. In both human subcutaneous adipose tissue and
isolated human adipocytes, ALK7 expression was markedly higher
than in the other tissues (Fig. 1B).
Of the type II receptors, the adipose tissue expression of the
ActRII gene was slightly above and the adipose tissue expression
of the ActRIIB gene was slightly below the mean expression in
the reference tissues.
Adipose tissue expression of ALK7 and INHBB in lean and obese siblings
in relation to clinical parameters
The high expression of genes encoding the activin receptor ALK7
and the activin subunit INHBB in human adipose tissue opens the
possibility that locally produced activin B inﬂuences adipose tissue
function. We therefore examined ALK7 and INHBB expression in
relation to obesity and components of the metabolic syndrome. In
the SOS Sib Pair study, adipose tissueALK7expressionwasmarkedly
decreased in the obese compared to the lean siblings (p = 4  1031).
In contrast, INHBB expression levels were increased in the obese
compared to the lean siblings (Fig. 2, p = 6  1013).
Fig. 3 shows the correlations between ALK7 and INHBB expres-
sion and clinical parameters in the SOS Sib Pair study, as well as the
difference between the correlation coefﬁcients for each transcript
in lean and obese subjects.
With the exception for a strong positive correlation with HDL-C,
there were signiﬁcant negative correlations between ALK7 and
clinical parameters in both groups. For measures of glucose and
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Fig. 1. Expression of activin subunits and activin receptors in human adipose tissue analyzed by microarray (A) and ALK7 expression analyzed by real-time PCR (B). (A) For
each gene, the expression in subcutaneous (scAT) and omental adipose tissue (omAT) relative to the mean expression level in 65 reference tissues (dashed line) is shown. (B)
ALK7 gene expression in human adipose tissue (mean ± SEM, n = 3) and adipocytes (mean ± SEM, n = 3) compared with other human tissues.
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ent in lean and obese subjects.
For INHBB, there were positive correlations with clinical
parameters in the lean subjects, whereas the correlations wereconsiderably weaker or lost in the obese subjects. In addition, there
was a negative correlation between HDL-C and INHBB expression
in both groups. The correlation coefﬁcients for INHBB and mea-
sures of fat mass differed in lean and obese groups.
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Fig. 2. ALK7 (left) and INHBB (right) expression in lean (n = 90) and obese (n = 90) siblings from the SOS Sib Pair study measured by DNA microarray.
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When the relationship between ALK7 mRNA and INHBB mRNA
was analyzed there was a negative correlation in the lean group
(r =0.64, p = 7  1012), and this persisted after controlling for sex
and age (r = 0.58, p = 2  109). In the obese subjects, there was
no correlation (r = 0.03, p = 0.8; Fig. 4A) even after controlling for
sex and age (r =0.16, p = 0.15), and the slope was signiﬁcantly dif-
ferent for the lean vs obese (p < 0.001; Fig. 4A) according to a general-
ized linearmodel. Thus, the relationshipbetween the ligand, encoded
by INHBB, and the receptor, encoded by ALK7, was different in lean
and obese subjects. The correlations between INHBB and measures
of body fat differed between lean and obese groups (Fig. 3). To deter-
mine if obesity inﬂuenced the relationship between the two tran-
scripts, we performed the analysis after controlling for fat mass in
addition tosexandage and found that therewas still a signiﬁcant cor-
relation in the lean group (r =0.52, p = 2  107) and no correlation
in theobesegroup(r =0.17,p = 0.13). Therewerealso severaldiffer-
ences in the relation between gene expression levels andmeasures of
carbohydrate metabolism in the two groups (Fig. 3). We therefore
subdivided all subjects into quartiles of the HOMA-IR index. In the
subjects with the highest HOMA-IR index, there was no correlation
betweenALK7 expression and INHBB expression. Inmarked contrast,
in the three other quartiles therewere highly signiﬁcant correlations
between ALK7 and INHBB expression (p < 2  105 for each of the
three quartiles after adjusting for sex and age). Since HOMA-IR is
derived fromglucose and insulin levels, we next performed the same
calculations for insulin and glucose quartiles. For insulin, the pattern
was strikingly similar to that seen for HOMA-IR, i.e. a loss of correla-
tion between ALK7 and INHBB expression in the highest quartile
(r = 0.12, p = 0.4) and signiﬁcant correlations in the remaining quar-
tiles (r = 0.63, p = 5  106; r = 0.64, p = 6  106; r = 0.61,
p = 1  105, respectively). Hence, the slope was signiﬁcantly differ-
entbetween the subjects fromthe three lowest insulinquartiles com-
pared to the subjects from the highest insulin quartile (p < 0.001;
Fig. 4B), according to a generalized linear model. For glucose, there
were signiﬁcant correlations between the two genes (p6 0.001 for
each quartile after adjusting for sex and age).
Discussion
In this study,wehave extendedour previous observation that the
beta B subunit, which homodimerizes to form activin B, is predomi-nantly expressed in human adipose tissue [2] and here demonstrate
that the activin B receptor ALK7 is adipocyte speciﬁc. There were
highly signiﬁcant differences in the expression of both ALK7 and
INHBB in lean and obese subjects and ALK7 and INHBB expression
correlated with several indicators of the metabolic syndrome. In
addition, the expression of the two transcripts correlated but only
in lean subjects and subjects with normal glucose tolerance.
Activins are involved in various physiological processes, such as
cell proliferation, immune function,wound repair and reproduction,
and exert their effects inmany tissues [1,4,6]. Our data clearly show
that receptors required for activin B signaling are expressed in adi-
pose tissue. The ﬁndings that both ALK7 and INHBB are expressed
at high levels in adipocytes and that the adipocyte is their main site
of expression indicate that the activin B signaling system is impor-
tant for adipose tissue function. This idea is supported by our obser-
vation that both INHBB and ALK7 expression are highly regulated by
obesity and the expression levels correlate with metabolic parame-
ters. Furthermore, our study shows that there is an altered relation-
ship between ALK7 and INHBB expression in subjects with
hyperinsulinemia, opening the possibility that activin B signaling
is involved inmetabolic control or that insulinaffects theexpression.
ALK7 expression has previously been detected in the brain, pan-
creas and colon, however, adipose tissue was not included in the
analysis [11]. In rodents, ALK7 expression is expressed in several
organs including brain [12], ovary [13], pancreas [14] and adipose
tissue [15]. In our study, both microarray analysis and real-time
PCR showed that adipose tissue and adipocytes display the highest
expression of ALK7. In the analysis of microarray proﬁles from a
large number of human tissues we also found high expression of
the ALK7 gene in the mammary gland. However, in mammary
gland microarray proﬁles, high expression of adipocyte speciﬁc
markers, such as leptin and adiponectin, was also observed,
strongly suggesting that the high ALK7 gene expression was due
to the presence of adipose tissue in the biopsies. The very high
and speciﬁc expression of ALK7 in adipose tissue suggests that sig-
naling through this receptor inﬂuences adipose tissue function. In a
very recent report, it was shown that disease genes often are spe-
ciﬁcally expressed in the normal tissue corresponding to the tissue
affected by the disease [16], supporting the idea that ALK7 could be
involved in obesity and metabolic disease.
Recent studies in rodents and in vitro also support our hypothesis
that the activin B receptor ALK7 is implicated in the regulation of
metabolism and adipose tissue function. ALK7 is speciﬁcally
Fig. 3. Spearman rank correlations between ALK7 and INHBB transcript levels and clinical traits in lean (n = 90) and obese (n = 90) subjects. Correlation coefﬁcients (r) and
their 95% conﬁdence intervals, as derived from Fisher’s z-transformation, are represented by vertical marks and horizontal lines, respectively. Correlations are statistically
signiﬁcant if their conﬁdence interval does not include zero (vertical axes). Corr. Diff. indicates whether correlations between clinical parameters and ALK7 or INHBB were
signiﬁcantly different between lean and obese subjects. Differences in r between lean and obese are signiﬁcant if either conﬁdence interval does not include r of the other.
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suggesting that activin B is involved in adipogenesis. ALK7deﬁcient mice have hyperinsulinemia, reduced insulin sensitivity
and impaired glucose tolerance [15,18]. Interestingly, in our study
Fig. 4. Correlations between INHBB and ALK7 gene expression. (A) The relation between INHBB and ALK 7 in lean (n = 90) and obese (n = 90) siblings. (B) The relation between
INHBB and ALK7 in subjects in the highest quartile (n = 44) with respect to serum insulin levels compared to the rest of the group (n = 134). The slopes for the relation
between INHBB and ALK7 expression were signiﬁcantly different in lean and obese (p < 0.001) as well as between subjects in the highest quartile with respect to serum
insulin levels compared to the rest of the group (p < 0.001). Data are standardized to mean = 0 and SD = 1.
314 L.M.S. Carlsson et al. / Biochemical and Biophysical Research Communications 382 (2009) 309–314there were negative correlations between ALK7 expression serum
insulin, HOMA, C-peptide and plasma glucose which is in line with
the observations in the ALK7 deﬁcient mice. However, mice lacking
ALK7 are partially resistant to diet-induced obesity, have smaller
adipocytes, smaller epididymal fat pads and increasedaccumulation
of lipids in the liver. In human subjects, we found negative correla-
tions between ALK7 expression and obesity, indicating that there
may be species differences or that a complete loss of function is re-
quired to affect the amount of adipose tissue and adipocyte size. In
our study, ALK7 expression correlated with serum lipid levels but
no data are available on serum lipids in AKL7 deﬁcient mice.
In conclusion, human adipose tissue expresses receptors
required for paracrine or autocrine effects of activin B. The effects
of obesity on adipose tissue expression of ALK7 and INHBB genes,
the strong correlations with markers of the metabolic syndrome
and the dysregulation between ligand and receptor transcripts in
subjects with glucose intolerance indicate that the adipokine acti-
vin B has hitherto unrecognized metabolic effects.
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